#### **Clinical Research Submission**

Last Modified: 8/7/2025, 4:47:17 pm

#### 1. Administration

Name of Research Principal: Dr.PPoonam Baral

Department: Clinical Pharmacology and Therapeutics

Study Title: Knowledge ,Attitude and Practices of caregivers in diarrheal diseases of under 5

children with special reference to the use of medications

Review Requested: Full Committee Review

Submission Date: 8/7/2025

Submitted At: 8/7/2025, 6:02:22 am

Version Number: 01 Date: 29/6/2025

Protocol Number: AB12 Employee code: 51046

Summary:

Selected Elements:

Other Reason:

### 2. Investigators

#### Researchers

Name: Dr.Poonam Baral

Designation: Senior resident

Qualification: MBBS MD

Department: Clinical Pharmacology and Therapeutics

Investigator Type: Principal Investigator

Employee code: 51046

Alternate Gmail: shanmukasagar2019@gmail.com

Contact: 9937840937

,

Name: Dr.Abinash Panda

Designation: Associate professor

Qualification: MBBS MD Department: Pharmacology Investigator Type: Guide Employee code: 51046

Alternate Gmail: shanmukasagar2021@gmail.com

Contact: 9874563452

,

Name: Dr.JAYANTI Prava Behera

Designation: PROFESSOR Qualification: MBBS MD

Department: PHARMACOLOGY

Investigator Type: hod Employee code: 51046

Alternate Gmail: shanmukasagar2023@gmail.com

Contact: 9987879986

### **Funding Details**

Funding Source: self-funding

Total Estimated Budget: ₹ 50000

Proposed Budget: ₹ 50000 Cost Per Patient: ₹ 50 Total Project Cost: ₹ 50000

NIMS Investigations:

• Name: CYP 3A4 Study

**Cost:** 500

**Is Outsourced:** Yes

Outsourced Investigations:

Name:

Cost: Lab: NABL:

false false

#### **Overview of the Research**

Summary: To study the genetic profile of patients on warfarin

Type of Study: cross-sectional

Other Study Type: null

External Laboratory Involved: No

Specify (if External Lab):

Justification: To simplify drug dosing

Sample Size: 50

Employee code: 51046

### **Participants**

Type of Participants: patient

Specify (if applicable): N/A

Justification:

Additional Safeguards:

Reimbursement Details:

Advertisement Details:

Payment Type: No

Advertisement Type: No Employee code: 51046

Vulnerable Groups:

#### **Benefits Details**

Reimbursement Details:

Risk Management Strategy:

Anticipated Type of Benefits: No

Participant Benefits: Indirect

Society Benefits: Indirect

Improvement Benefits: Direct

Employee code: 51046

#### **Consent Details**

Seeking Waiver of Consent Type: No

Specify:

Employee code: 51046 Version Number: 01

Date: 8/7/2025 Subject: No

Certificates: No

Selected Languages: Telugu

Telugu

Version: cpt/tel Date: 8/7/2025

PIS Selected Items:

- Statement that study involves research & explain purpose of research
- Statement that consent & participation are voluntary
- Expected Risks and benefits to the study subject
- Alternatives procedures / therapies available
- Contact information of PI and Member Secretary of EC
- Financial compensation and medical management in SAE
- Right to withdraw from study at any time
- Expected duration of participation
- Maintenance of Confidentiality
- Responsibility of subject

Summary:

Waiver Selected Elements:

# **Compensation & Payment Details**

Waiver of Consent Type: No

Specify: hksfhkshf

Compensation for Research-Related Injury: Yes

Specific Compensation Details: fhskhfksfh

Employee code: 51046

## **Storage and Access Details**

Control Details: documents will be kept under lock and key

Access Details:

Sample Access Type: Yes

Sample Details: Unidentified Document Access Type: Yes Drugs Access Type: NA

Employee code: 51046

null

## **Additional Support Information**

Support Type: No Additional Details: Employee code: 51046

#### **Declaration**

#### **Selected Declarations:**

- • I/We certify that the information provided in this application is complete and correct.
- I/We confirm that all investigators have approved the submitted version of proposal /related documents
- I/We confirm that this study will be conducted in accordance with the latest ICMR
  National Ethical Guidelines for Biomedical and Health Research involving
  HumanParticipants and other applicable regulations and guidelines including
  responsible
- I/We will comply with all policies and guidelines of the institute and affiliated / collaborating institutions wherever applicable
- I/We confirm that we shall submit any protocol amendments, adverse events
  report, significant deviations from protocols, regular progress reports and a final report
  and also participate in any audit of the study if needed
- I/We confirm that we will maintain accurate and complete records of all aspects of the study.
- I/We will protect the privacy of participants and assure safety and confidentiality of study data and biological samples.

Principal Investigator: Dr. Poonam Baral

Date: 8/7/2025 Signature: poonam

<>

Co-PI / Guide: Dr. Padmaja

Date: 8/7/2025

Signature: Padmaja

<>

HOD: Dr. P Usharani

Date: 8/7/2025

Signature: Usharani

# 14. Checklist

Cover letter enlisting all documents enclosed	🕏 View File
Brief CV of all Investigators (updated, signed and dated)	<sup>†</sup> View File
EC clearance of other centers	File: null
Good Clinical Practice (GCP) training of investigators in last 3 years	View File
CRF / Interview guides / Focused Group Discussions (English and translated)	View File
Copy of the detailed protocol (clearly identified numbered and dated) and synopsis	₹ View File
MOU between collaborating partners	File: null
Advertisement / material to recruit participants	File: null
Assent form for minors (12-18 years)	File: null
Participant Information Sheet (PIS) and Informed Consent Form (ICF)	₹ View File
Insurance policy / participant coverage details	File: null